3 New Hair Loss Treatments Target Women After 30-Year Gap

For 78 million Americans dealing with hair loss, the treatment menu hasn't changed much since 1997. Women have been especially stuck, often excluded from clinical trials built around male hormones and left with limited options that didn't address their specific needs.

That drought is finally ending. Three drugs now in late-stage testing are taking entirely different approaches to hair regrowth, and two were designed with women as equal participants from the start.

VDPHL01 from Veradermics is an extended-release oral pill that delivers the benefits of minoxidil without the cardiovascular risks of older formulations. It's non-hormonal, making it suitable for both men and women. The April 2026 Phase 2/3 results showed robust hair growth in all dosing groups, and a dedicated women's trial is actively recruiting participants.

Clascoterone 5% from Cosmo Pharmaceuticals blocks DHT directly at the hair follicle without entering the bloodstream. That local action is the game-changer: unlike finasteride, which affects hormones throughout the body, clascoterone stays where it's applied. The Phase 3 trials enrolled 1,465 people across the US and Europe, making it the largest topical hair loss study ever conducted.

PP405 from Pelage Pharmaceuticals goes deeper still, targeting dormant stem cells inside follicles to restart growth at the cellular level. The Phase 2a trial included men and women across diverse hair types and found significant clinical response in people with higher-degree hair loss after just four weeks of treatment.

The Bright Side shines through the timelines. VDPHL01 is targeting regulatory submission in early 2027 with potential market availability by late 2027 or early 2028. Clascoterone already has regulatory submissions underway in the US and Europe following its 12-month safety follow-up completed in spring 2026.

While these new treatments move through final approvals, dermatologists point to low-level laser therapy as an evidence-backed option that works through a completely different mechanism than any drug. A 2026 study tracking patients for 12 months found sustained improvements in hair density, with even better results when combined with existing minoxidil treatment.

The shift represents something bigger than new drugs: it's the pharmaceutical industry finally building clinical trials that include women as full participants rather than afterthoughts.

Real solutions for hair loss are coming, built for everyone who needs them.